轻中度哮喘的临床缓解:发病率、影响因素和稳定性

Mana Ishizuka MD, Naoya Sugimoto MD, PhD, Konomi Kobayashi MD, Yuri Takeshita MD, PhD, Sahoko Imoto MD, PhD, Yuta Koizumi MD, PhD, Yusuke Togashi MD, Yutaro Tanaka MD, Maki Nagata MD, Saya Hattori MD, Yuki Uehara MD, Yuki Suzuki MD, PhD, Hikaru Toyota MD, PhD, Satoru Ishii MD, PhD, Hiroyuki Nagase MD, PhD
{"title":"轻中度哮喘的临床缓解:发病率、影响因素和稳定性","authors":"Mana Ishizuka MD,&nbsp;Naoya Sugimoto MD, PhD,&nbsp;Konomi Kobayashi MD,&nbsp;Yuri Takeshita MD, PhD,&nbsp;Sahoko Imoto MD, PhD,&nbsp;Yuta Koizumi MD, PhD,&nbsp;Yusuke Togashi MD,&nbsp;Yutaro Tanaka MD,&nbsp;Maki Nagata MD,&nbsp;Saya Hattori MD,&nbsp;Yuki Uehara MD,&nbsp;Yuki Suzuki MD, PhD,&nbsp;Hikaru Toyota MD, PhD,&nbsp;Satoru Ishii MD, PhD,&nbsp;Hiroyuki Nagase MD, PhD","doi":"10.1016/j.jacig.2025.100431","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Although clinical remission (CR) of severe asthma has been extensively investigated, CR of mild-to-moderate asthma remains unexplored.</div></div><div><h3>Objective</h3><div>This study aimed to determine CR rates, contributing factors, and stability in patients with mild-to-moderate asthma.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 263 patients with asthma. Three-component CR was defined as no exacerbation, no daily oral corticosteroid receipt, and an Asthma Control Test score equivalent to that of the well control; 4-component CR included these parameters plus forced expiratory volume in 1 second of ≥80% predicted. CR during the 1 year and stability of CR over 10 years were retrospectively analyzed in patients with mild-to-moderate and severe asthma.</div></div><div><h3>Results</h3><div>The CR rates were significantly higher (4-component, 73.2%; 3-component, 81.0%) in patients with mild-to-moderate asthma compared with the CR rate in patients with severe asthma (4-component, 33.9%; and 3-component, 30.6%). A lower smoking index contributed to 3- and 4-component CR. Lower body mass index contributed to 3-component remission, and later onset and shorter asthma duration contributed to 4-component remission. In patients experiencing 4-component remission 10 years before, 80.3% maintained disease in remission; 89.1% of patients experiencing 3-component remission maintained disease in remission. In patients with disease that did not maintain 4-component CR after 10 years, predicted forced expiratory volume decreased, but no differences in inhaled corticosteroid and long-acting β-agonists/long-acting muscarinic antagonists receipt were detected between 10 years ago and the present. The current muscarinic antagonist receipt remained low, at 16.7%.</div></div><div><h3>Conclusion</h3><div>CR, including normalized forced expiratory volume, is obtainable and sustainable in most Japanese patients with mild-to-moderate asthma. Assessing CR in these patients may help avoid undertreatment and reduce future risks.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 2","pages":"Article 100431"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical remission of mild-to-moderate asthma: Rates, contributing factors, and stability\",\"authors\":\"Mana Ishizuka MD,&nbsp;Naoya Sugimoto MD, PhD,&nbsp;Konomi Kobayashi MD,&nbsp;Yuri Takeshita MD, PhD,&nbsp;Sahoko Imoto MD, PhD,&nbsp;Yuta Koizumi MD, PhD,&nbsp;Yusuke Togashi MD,&nbsp;Yutaro Tanaka MD,&nbsp;Maki Nagata MD,&nbsp;Saya Hattori MD,&nbsp;Yuki Uehara MD,&nbsp;Yuki Suzuki MD, PhD,&nbsp;Hikaru Toyota MD, PhD,&nbsp;Satoru Ishii MD, PhD,&nbsp;Hiroyuki Nagase MD, PhD\",\"doi\":\"10.1016/j.jacig.2025.100431\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Although clinical remission (CR) of severe asthma has been extensively investigated, CR of mild-to-moderate asthma remains unexplored.</div></div><div><h3>Objective</h3><div>This study aimed to determine CR rates, contributing factors, and stability in patients with mild-to-moderate asthma.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 263 patients with asthma. Three-component CR was defined as no exacerbation, no daily oral corticosteroid receipt, and an Asthma Control Test score equivalent to that of the well control; 4-component CR included these parameters plus forced expiratory volume in 1 second of ≥80% predicted. CR during the 1 year and stability of CR over 10 years were retrospectively analyzed in patients with mild-to-moderate and severe asthma.</div></div><div><h3>Results</h3><div>The CR rates were significantly higher (4-component, 73.2%; 3-component, 81.0%) in patients with mild-to-moderate asthma compared with the CR rate in patients with severe asthma (4-component, 33.9%; and 3-component, 30.6%). A lower smoking index contributed to 3- and 4-component CR. Lower body mass index contributed to 3-component remission, and later onset and shorter asthma duration contributed to 4-component remission. In patients experiencing 4-component remission 10 years before, 80.3% maintained disease in remission; 89.1% of patients experiencing 3-component remission maintained disease in remission. In patients with disease that did not maintain 4-component CR after 10 years, predicted forced expiratory volume decreased, but no differences in inhaled corticosteroid and long-acting β-agonists/long-acting muscarinic antagonists receipt were detected between 10 years ago and the present. The current muscarinic antagonist receipt remained low, at 16.7%.</div></div><div><h3>Conclusion</h3><div>CR, including normalized forced expiratory volume, is obtainable and sustainable in most Japanese patients with mild-to-moderate asthma. Assessing CR in these patients may help avoid undertreatment and reduce future risks.</div></div>\",\"PeriodicalId\":75041,\"journal\":{\"name\":\"The journal of allergy and clinical immunology. Global\",\"volume\":\"4 2\",\"pages\":\"Article 100431\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The journal of allergy and clinical immunology. Global\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772829325000323\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The journal of allergy and clinical immunology. Global","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772829325000323","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/30 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

虽然重度哮喘的临床缓解(CR)已被广泛研究,但轻中度哮喘的临床缓解(CR)仍未被探索。目的本研究旨在确定轻中度哮喘患者的CR率、影响因素和稳定性。方法对263例哮喘患者进行回顾性分析。三组分CR定义为无加重,无每日口服皮质类固醇,哮喘控制测试得分与对照组相当;四组分CR包括这些参数加上1秒用力呼气量≥预测值的80%。回顾性分析轻中度和重度哮喘患者1年CR和10年CR的稳定性。结果CR率显著高于对照组(4组分,73.2%;3组分,81.0%),而重度哮喘患者的CR率(4组分,33.9%;3组分占30.6%)。较低的吸烟指数有助于3组分和4组分的CR,较低的体重指数有助于3组分的缓解,较晚的发病时间和较短的哮喘持续时间有助于4组分的缓解。在10年前经历4组分缓解的患者中,80.3%的患者保持疾病缓解;经历三组分缓解的患者中,89.1%的患者病情维持在缓解期。在10年后未维持4组分CR的疾病患者中,预测用力呼气量减少,但在10年前和现在之间,吸入皮质类固醇和长效β激动剂/长效毒菌碱拮抗剂的使用未检测到差异。目前的毒蕈碱拮抗剂使用率仍然很低,为16.7%。结论在大多数日本轻中度哮喘患者中,包括正常化用力呼气量在内的cr是可获得和可持续的。评估这些患者的CR可能有助于避免治疗不足并降低未来的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Clinical remission of mild-to-moderate asthma: Rates, contributing factors, and stability

Background

Although clinical remission (CR) of severe asthma has been extensively investigated, CR of mild-to-moderate asthma remains unexplored.

Objective

This study aimed to determine CR rates, contributing factors, and stability in patients with mild-to-moderate asthma.

Methods

We retrospectively analyzed 263 patients with asthma. Three-component CR was defined as no exacerbation, no daily oral corticosteroid receipt, and an Asthma Control Test score equivalent to that of the well control; 4-component CR included these parameters plus forced expiratory volume in 1 second of ≥80% predicted. CR during the 1 year and stability of CR over 10 years were retrospectively analyzed in patients with mild-to-moderate and severe asthma.

Results

The CR rates were significantly higher (4-component, 73.2%; 3-component, 81.0%) in patients with mild-to-moderate asthma compared with the CR rate in patients with severe asthma (4-component, 33.9%; and 3-component, 30.6%). A lower smoking index contributed to 3- and 4-component CR. Lower body mass index contributed to 3-component remission, and later onset and shorter asthma duration contributed to 4-component remission. In patients experiencing 4-component remission 10 years before, 80.3% maintained disease in remission; 89.1% of patients experiencing 3-component remission maintained disease in remission. In patients with disease that did not maintain 4-component CR after 10 years, predicted forced expiratory volume decreased, but no differences in inhaled corticosteroid and long-acting β-agonists/long-acting muscarinic antagonists receipt were detected between 10 years ago and the present. The current muscarinic antagonist receipt remained low, at 16.7%.

Conclusion

CR, including normalized forced expiratory volume, is obtainable and sustainable in most Japanese patients with mild-to-moderate asthma. Assessing CR in these patients may help avoid undertreatment and reduce future risks.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
The journal of allergy and clinical immunology. Global
The journal of allergy and clinical immunology. Global Immunology, Allergology and Rheumatology
CiteScore
0.70
自引率
0.00%
发文量
0
审稿时长
92 days
期刊最新文献
Immunoglobulin replacement therapy in primary immunodeficiency disorders: Pragmatic review and evidence mapping Four doses of coronavirus disease 2019 vaccination for patients with inborn errors of immunity compared to 3 doses for healthy individuals Phenotyping treatment-naive uncontrolled asthma in adults: A primary care framework Pathobiology of atopic dermatitis and association with disease severity after acute oral steroid treatment Hereditary alpha-tryptasemia demonstrates relative basophil enrichment without signs of cellular hyperreactivity
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1